Bio-Techne (TECH) Stock Outlook 2026: A Great Tools Franchise, Priced for the Rebound
Bio-Techne (TECH) stock outlook for 2026: the reagent and Simple Western moat, the bet on a biopharma R&D spending rebound, the growth-stall risk, a 52-week-high valuation check, peer comparison, and US tax and position-sizing scenarios.